INOVIO Announces Pricing of Approximately $75 Million Public Offering
INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 58,747,235 shares of its common stock at a public offering price of $1.05 per share of common stock and pre-funded warrants to purchase 12,681,337 shares of common stock at an offering price of $1.049 per pre-funded warrant, in each case before underwriting discounts and commissions. INOVIO also granted the underwriters an option for a period of 30 days to purchas